Literature DB >> 11080057

Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease.

K A Nath1, V Shah, J J Haggard, A J Croatt, L A Smith, R P Hebbel, Z S Katusic.   

Abstract

We investigated a transgenic mouse model of sickle cell disease, homozygous for deletion of mouse beta-globin and containing transgenes for human beta(S) and beta(S-antilles) globins linked to the transgene for human alpha-globin. In these mice, basal cGMP production in aortic rings is increased, whereas relaxation to an endothelium-dependent vasodilator, A-23187, is impaired. In contrast, aortic expression of endothelial nitric oxide synthase (NOS) is unaltered in sickle mice, whereas expression of inducible NOS is not detected in either group; plasma nitrate/nitrite concentrations and NOS activity are similar in both groups. Increased cGMP may reflect the stimulatory effect of peroxides (an activator of guanylate cyclase), because lipid peroxidation is increased in aortae and in plasma in sickle mice. Despite increased vascular cGMP levels in sickle mice, conscious systolic blood pressure is comparable to that of aged-matched controls; sickle mice, however, evince a greater rise in systolic blood pressure in response to nitro-L-arginine methyl ester, an inhibitor of NOS. Systemic concentrations of the vasoconstrictive oxidative product 8-isoprostane are increased in sickle mice. We conclude that vascular responses are altered in this transgenic sickle mouse and are accompanied by increased lipid peroxidation and production of cGMP; we suggest that oxidant-inducible vasoconstrictor systems such as isoprostanes may oppose nitric oxide-dependent and nitric oxide-independent mechanisms of vasodilatation in this transgenic sickle mouse. Destabilization of the vasoactive balance in the sickle vasculature by clinically relevant states may predispose to vasoocclusive disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080057     DOI: 10.1152/ajpregu.2000.279.6.R1949

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  38 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Vasculature and kidney complications in sickle cell disease.

Authors:  Karl A Nath; Zvonimir S Katusic
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

3.  Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.

Authors:  Candice Bereal-Williams; Roberto F Machado; Vicki McGowan; Amy Chi; Christian J Hunter; Gregory J Kato; Lori Hunter; Carole K Dalby; Kristine Partovi Hauser; Anitaben Tailor; Richard O Cannon
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

4.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

5.  Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Authors:  Gregory J Kato; Matthew Hsieh; Roberto Machado; James Taylor; Jane Little; John A Butman; Tanya Lehky; John Tisdale; Mark T Gladwin
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

6.  Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.

Authors:  Dhananjay K Kaul; Xiao-du Liu; Hee-Yoon Chang; Ronald L Nagel; Mary E Fabry
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 7.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

8.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

9.  Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Authors:  Terika P Smith; Alyssa M Schlenz; Jeffrey C Schatz; Rangan Maitra; Sarah M Sweitzer
Journal:  Blood Cells Mol Dis       Date:  2014-11-26       Impact factor: 3.039

10.  Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.

Authors:  Dhananjay K Kaul; Xiaoqin Zhang; Trisha Dasgupta; Mary E Fabry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.